EXOSENS PROM (EXENS) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of EXOSENS PROM stock €52.42, price €51.65, upside +1.5%, quality 46 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
29‑month range €16.97 – €72.57 · fair‑value band €26.54 – €70.72 · the €51.65 price screens below the €52.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow EXOSENS PROM in your weekly email
Every Wednesday you see whether EXOSENS PROM is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging.
Show moreShow less
The company offers image intensifier tubes; cameras, sensors, modules and cores, and imaging systems and solutions, including UV missile warning solution, atmospheric sounder, and spectroradiometer; and detection and imaging products for ions and electrons, photons, and neutrons, as well as micro pore optics and components, such as phosphor screens, resistive glass products, microchannel plates, and electron generator arrays.
It also provides bare and energy compensated Geiger- Müller tubes; gamma and neutron detectors; mineral insulated extensions; and silicon photodiodes, as well as methane airborne detection solutions.
The company sells its products under the Exosens, Photonis, Xenics, Telops, El-Mul, and Noxant brand names. It serves defense and surveillance, life sciences and environment, industrial control, and nuclear markets. The company was founded in 1937 and is headquartered in Mérignac, France.
Stock analysis
EXOSENS PROM (EXENS) currently trades at €51.65, while our model-based Fair Value estimate is €52.42, so the stock looks roughly fairly valued today (gap 1.5%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €28.69 per share, and 0 of the 24 models we run sit above the €51.65 price.
Bear case: the Economic Profit group reads lowest at €13.80, and 24 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: €26.54 (bear) to €70.72 (bull), the price of €51.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Industrials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
EXOSENS PROM reported revenue of €468M in FY2025 versus €166M in FY2021, a compound +29.6%/yr. Reported net income was €42.7M in FY2025.
Key figures
Market cap €2.6B Mid · P/E ratio 123.0 · P/S ratio 5.84 · EPS (TTM) €0.4200 · Dividend yield 0.6% · Net margin 6.0% · Return on equity 12.7% · Return on assets (EBIT) 8.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 29% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −23% fair-value upside, at 1%, EXENS screens cheaper than that median.
Fair Value models
Bear€26.54Fair Value €52.42Bull€70.72
Price €51.65 · Upside +1.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.1026 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+18.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.6%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+24.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+24.0%
Dividend (yield on the price)0.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 22%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +27.4% a year for the price and +10.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (19 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Exosens draws strength from its expanding supply of neutron detectors for U.S. small modular reactors alongside defense imaging contracts, yet thin public evidence leaves any durable competitive advantage unproven.
Main risk: Thin evidence on competitive strengths leaves contract sustainability in nuclear and defense areas uncertain and could reduce future order visibility.
Exosens is extending its nuclear instrumentation reach by supplying neutron detectors for successful U.S. small modular reactor criticality tests under the Department of Energy program. This adds to its defense imaging contracts and capacity expansions in night vision tubes. Our models currently see the shares as overvalued. Will the nuclear and defense momentum deliver sustained outperformance, or will the premium valuation prove difficult to justify?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Aerospace & Defense · 238 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside+1.5% · Top 25%
Profitability
Return on equity (12 months)12.7% · Above median
Return on assets4.9% · Above median
Net margin (12 months)6.0% · Below median
Operating margin (12 months)12.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)15.3% · Above median
Dividend yield (12 months)0.6% · Below median
Balance sheet
Debt / equity0.56× · Highest 25%
Valuation Multiplesvs Aerospace & Defense median · lower = cheaper
P/E (12 months)123.0× · Priciest 25%
P/B6.58× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EXOSENS PROM Fair Value". https://www.fairvalue-calculator.com/stock/EXENS
Frequently asked questions
Is EXOSENS PROM (EXENS) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €52.42 versus a price of €51.65, about +1% upside (fairly valued).
What is the fair value of EXENS?
Our model-based fair value for EXOSENS PROM is €52.42 (as of Nov 6, 2026), built from audited fundamentals. The current price: €51.65.
What is the quality score of EXENS?
EXOSENS PROM has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EXOSENS PROM (EXENS)?
Our model-based price target is the fair value of €52.42 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario €26.54, optimistic scenario €70.72. It is a calculation from audited fundamentals, not an analyst target.
What is the EXOSENS PROM stock forecast for 2026?
Our models put fair value at €52.42, about +1% upside versus a price of €51.65 (fairly valued). Cautious scenario €26.54, optimistic scenario €70.72. The calculation is refreshed regularly with new filings.
What is the revenue of EXOSENS PROM (EXENS)?
EXOSENS PROM reported trailing-twelve-month revenue of about €502M (latest available figure, as of Nov 6, 2026).
Does EXOSENS PROM pay a dividend?
EXOSENS PROM currently shows a dividend yield of 0.58% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of EXOSENS PROM (EXENS) and when is the ex-dividend date?
EXOSENS PROM pays a dividend of €0.3 per share a year, a dividend yield of 0.6%. The last ex-dividend date was May 27, 2026. The payout ratio is 71.4% of earnings. Free cash flow covers the dividend 3.19 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into EXOSENS PROM (EXENS)?
For today's price to be fair in a discounted-cash-flow model, EXOSENS PROM would have to grow free cash flow by +30.2 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of EXENS use?
Our models discount EXOSENS PROM at 9.9 %: a base by market capitalisation (mid), damped by beta 0.84, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EXOSENS PROM that is +30.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has EXOSENS PROM (EXENS) delivered so far?
Over the past 5 years revenue at EXOSENS PROM grew +25.6 % a year. The price currently implies free-cash-flow growth of +30.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EXOSENS PROM (EXENS) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into EXOSENS PROM (+30.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EXOSENS PROM (EXENS)?
The free-cash-flow yield on the price is 1.84 %: that much free cash flow EXOSENS PROM produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EXOSENS PROM (EXENS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EXOSENS PROM it is €52.42 per share (as of Nov 6, 2026), against a price of €51.65. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is EXOSENS PROM stock overvalued or undervalued in 2026?
As of Nov 6, 2026, EXENS trades below its calculated fair value: price €51.65, fair value €52.42, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EXENS?
No. The price is what the market pays today (€51.65); the fair value is what the company's own numbers justify (€52.42). For EXOSENS PROM the two are €0.7700 per share apart. That gap is exactly why we show both numbers side by side.
How much is EXOSENS PROM worth?
The market values EXOSENS PROM at about €2.6B (market capitalisation, as of Nov 6, 2026). Per share that is €51.65; our models calculate a fair value of €52.42 per share.
What do the bullish and bearish scenarios say about EXENS?
Our models span a range for EXOSENS PROM: cautious scenario €26.54, base €52.42, optimistic €70.72 per share (as of Nov 6, 2026, price €51.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EXENS?
EXOSENS PROM trades at a price-to-earnings ratio of 123.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €52.42 is built from several models across several years. Other multiples: P/B 6.6, P/S 5.8, EV/EBITDA 29.7.
How solid is the balance sheet of EXOSENS PROM (EXENS)?
Balance-sheet figures for EXOSENS PROM (as of Nov 6, 2026): return on equity 12.7%, debt of 0.56 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is EXENS from its 52-week high?
EXOSENS PROM trades at €51.65, about 29% below its 52-week high of €72.57 and 27% above the low of €40.81 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €52.42 is for.
Which stocks are comparable to EXOSENS PROM?
From the same area (Industrials) we also value General Electric Company, RTX Corporation, Airbus SE, Safran SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EXOSENS PROM stock attractive at the current price?
The data as of Nov 6, 2026: price €51.65, calculated fair value €52.42 (+1%), Quality Score 46/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EXENS calculated?
We run EXOSENS PROM through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €52.42 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. EXOSENS PROM currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EXOSENS PROM (EXENS)?
The closing price on Nov 6, 2026 was €51.65. Our model-based fair value is €52.42, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EXOSENS PROM right now?
The model range is unusually wide (€26.54 to €70.72). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of EXOSENS PROM
How large is the market capitalisation of EXOSENS PROM (EXENS)?
The market capitalisation of EXOSENS PROM is €2.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EXOSENS PROM (EXENS)?
The price-to-sales ratio of EXOSENS PROM is 5.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EXOSENS PROM (EXENS)?
Earnings per share at EXOSENS PROM are €0.4200 (price ÷ EPS = P/E 123.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of EXOSENS PROM (EXENS)?
The dividend yield of EXOSENS PROM is 0.6% (payout 71.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EXOSENS PROM (EXENS)?
The net margin of EXOSENS PROM is 6.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EXOSENS PROM (EXENS)?
The return on equity (ROE) of EXOSENS PROM is 12.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EXOSENS PROM (EXENS)?
On an EBIT basis the return on assets of EXOSENS PROM is 8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EXOSENS PROM (EXENS)?
The operating margin of EXOSENS PROM is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EXOSENS PROM (EXENS)?
Revenue at EXOSENS PROM is growing +15.3% versus a year earlier (3y avg +32.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EXOSENS PROM (EXENS)?
Earnings per share at EXOSENS PROM are growing −45.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does EXOSENS PROM (EXENS) carry?
The net debt of EXOSENS PROM is €211M (fiscal year 2025, ≈ 4.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch EXOSENS PROM in the live analysis
One click puts EXOSENS PROM on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026